Loading data for PLX — first visit, this takes a few seconds.

提醒

Protalix BioTherapeutics ... (PLX)

NYSE American: PLX · 即時價格 · USD

2.61

+0.13 (5.24%)

收盤價： Aug 27, 2026, 3:59 PM

2.60

-0.57%

盤後: 7:37 PM

股價、關鍵數字和最新消息，都在這一頁。

5.24% (1D)

買價	2.61
市值	210.29M
營收 (ttm)	80.62M
淨利（ttm）	18.95M
	0.01
	0.23
	11.35
	4.21
P/B (ttm)	3.13
P/S (ttm)	2.61
財報日期	Aug 14, 2025

賣價	2.61
成交量	1,289,866
20 日平均成交量	668,560
開盤價	2.49
前收盤價	2.48
當日區間	2.48 - 2.65
52 週範圍	1.52 - 3.19
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombina...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 May 15, 1998

員工 226

證券交易所 NYSE American

股票代號 PLX

網站 https://www.protalix.com

完整的公司簡介

財務表現

Protalix BioTherapeutics 在 2025 年的營收為 52.74M，較前一年的 53.4M 減少 -1.23%。淨利為 -6.6M，較前期減少 -325.24%。

財務報表

財報驚奇

Protalix BioTherapeutics 已於 Aug 12, 2026 公布季度財報：

營收為 $33.75M 低於預期 $0, 年增 233.73% 成長.
每股盈餘為 0.05 超出預期 0.06, 年增 200.00% 成長.

下次財報發布

Protalix BioTherapeutics Inc. 的下次財報預計於 Aug 14, 2025, 開盤前。
分析師預估營收 ... 升級

新聞動態

1 週前 · Moby

Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary

Moby summary of Protalix BioTherapeutics, Inc.'s Q2 2026 earnings call

2 週前 · GuruFocus.com

Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ...

Revenue climbs 27% year-over-year, driven by higher Elfabrio sales to Chiesi, while the company advances its promising PRS-115 gout program.

3 月前 · Simply Wall St.

3 Penny Stocks With Market Caps Larger Than $100M To Consider

The market has climbed 1.2% in the last 7 days and an impressive 29% over the past year, with earnings forecasted to grow by 17% annually. While penny stocks might seem like a relic from earlier marke...

3 月前 · Moby

Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary

Moby summary of Protalix BioTherapeutics, Inc.'s Q1 2026 earnings call

3 月前 · GuruFocus.com

Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ...

Protalix BioTherapeutics Inc (PLX) reports a profitable quarter with significant milestone achievements and reaffirms its 2026 revenue guidance.

第 1 頁，共 2 頁